A detailed history of Hsbc Holdings PLC transactions in Charles River Laboratories International, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 81,894 shares of CRL stock, worth $13.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
81,894
Previous 98,475 16.84%
Holding current value
$13.8 Million
Previous $20.3 Million 20.7%
% of portfolio
0.01%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$187.96 - $245.29 $3.12 Million - $4.07 Million
-16,581 Reduced 16.84%
81,894 $16.1 Million
Q2 2024

Aug 12, 2024

BUY
$206.39 - $268.73 $4.38 Million - $5.7 Million
21,221 Added 27.47%
98,475 $20.3 Million
Q1 2024

May 15, 2024

BUY
$203.52 - $273.43 $4.31 Million - $5.79 Million
21,179 Added 37.77%
77,254 $20.9 Million
Q4 2023

Feb 12, 2024

SELL
$164.52 - $238.84 $1.16 Million - $1.69 Million
-7,068 Reduced 11.19%
56,075 $13.3 Million
Q3 2023

Nov 13, 2023

BUY
$194.44 - $217.61 $1.77 Million - $1.98 Million
9,102 Added 16.84%
63,143 $12.4 Million
Q2 2023

Aug 11, 2023

BUY
$183.71 - $210.25 $1.99 Million - $2.27 Million
10,813 Added 25.01%
54,041 $11.4 Million
Q1 2023

May 15, 2023

SELL
$191.89 - $259.92 $1.74 Million - $2.36 Million
-9,093 Reduced 17.38%
43,228 $8.72 Million
Q4 2022

Feb 14, 2023

BUY
$197.11 - $250.07 $3.11 Million - $3.94 Million
15,755 Added 43.09%
52,321 $11.4 Million
Q3 2022

Nov 14, 2022

BUY
$182.44 - $250.54 $38,859 - $53,365
213 Added 0.59%
36,566 $7.11 Million
Q2 2022

Aug 11, 2022

SELL
$204.13 - $302.4 $1.85 Million - $2.74 Million
-9,072 Reduced 19.97%
36,353 $7.91 Million
Q1 2022

May 16, 2022

BUY
$255.51 - $362.11 $373,811 - $529,766
1,463 Added 3.33%
45,425 $13.1 Million
Q4 2021

Feb 11, 2022

BUY
$351.38 - $448.68 $1.62 Million - $2.07 Million
4,617 Added 11.73%
43,962 $16.6 Million
Q3 2021

Nov 12, 2021

BUY
$372.64 - $458.3 $2.82 Million - $3.47 Million
7,563 Added 23.8%
39,345 $16.5 Million
Q2 2021

Aug 13, 2021

BUY
$294.17 - $371.65 $7.54 Million - $9.52 Million
25,615 Added 415.36%
31,782 $11.8 Million
Q1 2021

May 14, 2021

SELL
$249.67 - $299.48 $347,540 - $416,876
-1,392 Reduced 18.42%
6,167 $1.79 Million
Q4 2020

Feb 12, 2021

BUY
$222.0 - $252.62 $1.07 Million - $1.22 Million
4,811 Added 175.07%
7,559 $1.89 Million
Q3 2020

Nov 12, 2020

BUY
$175.56 - $226.45 $202,771 - $261,549
1,155 Added 72.5%
2,748 $622,000
Q2 2020

Aug 14, 2020

SELL
$118.84 - $189.72 $47,179 - $75,318
-397 Reduced 19.95%
1,593 $278,000
Q1 2020

May 15, 2020

SELL
$98.9 - $178.34 $523,378 - $943,775
-5,292 Reduced 72.67%
1,990 $255,000
Q4 2019

Feb 14, 2020

SELL
$126.05 - $152.76 $96,680 - $117,166
-767 Reduced 9.53%
7,282 $1.12 Million
Q3 2019

Nov 14, 2019

SELL
$125.07 - $143.67 $3.79 Million - $4.36 Million
-30,316 Reduced 79.02%
8,049 $1.07 Million
Q2 2019

Aug 13, 2019

BUY
$123.4 - $148.55 $4.04 Million - $4.86 Million
32,702 Added 577.47%
38,365 $5.44 Million
Q1 2019

May 15, 2019

SELL
$104.82 - $146.73 $682,168 - $954,918
-6,508 Reduced 53.47%
5,663 $822,000
Q4 2018

Feb 13, 2019

BUY
$105.09 - $137.23 $858,585 - $1.12 Million
8,170 Added 204.2%
12,171 $1.38 Million
Q3 2018

Nov 13, 2018

SELL
$112.11 - $134.54 $4.68 Million - $5.62 Million
-41,736 Reduced 91.25%
4,001 $538,000
Q2 2018

Aug 10, 2018

BUY
$102.37 - $117.25 $1.76 Million - $2.01 Million
17,178 Added 60.15%
45,737 $5.13 Million
Q1 2018

May 11, 2018

BUY
$98.19 - $115.2 $2.44 Million - $2.87 Million
24,883 Added 676.9%
28,559 $3.05 Million
Q4 2017

Feb 14, 2018

BUY
$100.43 - $118.09 $68,694 - $80,773
684 Added 22.86%
3,676 $403,000
Q3 2017

Nov 14, 2017

BUY
$96.72 - $109.26 $56,484 - $63,807
584 Added 24.25%
2,992 $323,000
Q2 2017

Aug 14, 2017

BUY
N/A
2,408
2,408 $244,000

Others Institutions Holding CRL

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.


  • Ticker CRL
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 50,863,300
  • Market Cap $8.56B
  • Description
  • Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...
More about CRL
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.